<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04117477</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0261</org_study_id>
    <nct_id>NCT04117477</nct_id>
  </id_info>
  <brief_title>Xylitol - Healthcare Associated Infection Reduction in Stem Cell Transplant Patients</brief_title>
  <official_title>Healthcare Associated Infection Reduction in Stem Cell Transplant Patients: a Randomized, Double-blind, Placebo-controlled Study Evaluating Twice Daily Xylitol Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The central hypothesis is that daily dental xylitol wipes, in addition to current oral care
      practice, are effective at reducing BSI from oral organisms, and decreasing the incidence of
      gingivitis, oral plaque, and oral ulcerations after SCT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our long-term goal is to develop and disseminate clinically relevant, and easily adoptable
      strategies to prevent BSI and improve outcomes after SCT. The overall objective of this
      proposal is to identify a clinically effective strategy to prevent or reduce BSI secondary to
      bacterial translocation through oral injured mucosa .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1, randomized, double-blind, placebo-controlled study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of bacteremia in the first 30 days post-HSCT with oral organisms</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of bacteremia in the first 30 days post-HSCT with any organism</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of dental plaque</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of gingival inflammation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of mucosal ulceration</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of oral mucositis</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of oral microbiome diversity</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of oral pathogenic bacteria burden</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">356</enrollment>
  <condition>Allogeneic Hematopoietic Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Xylitol wipes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo wipes</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xylitol</intervention_name>
    <description>Xylitol dental wipes</description>
    <arm_group_label>Xylitol wipes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo dental wipes</description>
    <arm_group_label>Placebo wipes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of any age undergoing SCT.

        Exclusion Criteria:

          -  Prior proton or photon radiation treatment for cancer of the oral cavity, head or
             neck; cranial boost in patients receiving total body irradiation; known history of
             allergy to xylitol; inability to use a mouth rinse or dental wipes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Bravo</last_name>
    <phone>513-803-4425</phone>
    <email>Jennifer.Bravo@cchmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katherine Hendy</last_name>
    <phone>513-803-7450</phone>
    <email>Katherine.Hendy@cchmc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Bravo</last_name>
      <phone>513-803-4425</phone>
      <email>Jennifer.Bravo@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Katherine Hendy</last_name>
      <phone>513-803-7450</phone>
      <email>Katherine.Hendy@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher Dandoy, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 3, 2019</study_first_submitted>
  <study_first_submitted_qc>October 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2019</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cross Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

